| HOME >> BIOLOGY >> TECHNOLOGY |
Capital expenditures (6,945) (3,809)
Net cash (used in) investing activities $ (9,845) $ (11,009)
CASH FLOWS FROM FINANCING ACTIVITIES:
(Repayments) under senior secured credit
term loan facility (2,071) (62,948)
Other 61 (56)
Net cash (used in) financing activities (2,010) (63,004)
Net (decrease) in cash and cash
equivalents $ (14,537) $ (15,962)
Cash and cash equivalents, beginning
of period 30,776 84,464
Cash and cash equivalents, end
of period $ 16,239 $ 68,502
WARNER CHILCOTT LIMITED
Reconciliation of Net Income / (Loss) to Adjusted EBITDA
(In thousands of U.S. dollars)
(Unaudited)
Quarter Ended
Mar-31-08 Mar-31-07
RECONCILIATION TO ADJUSTED EBITDA:
Net income / (loss) - GAAP $ 33,658 $ (4,502)
+ Interest expense, net 24,018 30,944
+ Provision / (benefit) for income taxes 4,017 (1,501)
+ Non-cash share-based compensation expense 1,810 1,685
+ Depreciation 2,925 2,354
+ Amortization of intangible assets 52,613 57,553
+ Litigation settlements - 7,500
Adjusted EBITDA of WCL, as defined $119,041 $ 94,033
+ Expenses of WCL and other 1,80
'/>"/>
| SOURCE Warner Chilcott Limited Copyright©2008 PR Newswire. All rights reserved |